Haier Biomedical's 2025 Independent Director Performance Report Released, Niu Jun Emphasizes Supervision and Governance Optimization

Log in to the Sina Finance APP and search for [Information Disclosure] to see more evaluation levels.

According to data from Zhongfang Network, Qingdao Haier Biomedical Co., Ltd. released the work report of independent director Niu Jun for the year 2025 on March 27, 2026. The report indicates that during his term in 2025, Niu Jun strictly adhered to relevant laws and regulations as well as the company’s articles of association, diligently performing his duties as an independent director. He personally attended all 6 board meetings, 2 shareholder meetings, and 3 special meetings for independent directors throughout the year, and expressed independent opinions on significant matters such as related party transactions and the re-election of directors, effectively safeguarding the legal rights and interests of the company and all shareholders, especially minority shareholders.

The report highlights Niu Jun’s supervision and attention to several key matters in 2025. These include the review and approval of the company’s expected daily related party transactions for 2025 and the related party transaction proposal for accounts receivable factoring, concluding that the pricing of related transactions is fair, and the procedures are compliant, not harming the company’s interests. Additionally, he reviewed the procedures and qualifications for the re-election of non-independent director Mr. Hu Xiangde, finding them to be in accordance with regulations. Niu Jun also continuously monitored the company’s periodic financial reports, internal controls, information disclosure, and the compensation of directors and senior executives, confirming their authenticity, accuracy, completeness, and compliance.

As a member of the company’s Strategy and ESG Committee and the chair of the Nomination Committee, Niu Jun gained in-depth understanding of the company’s operations and strategic development through participation in meetings, communication with management, and research visits. In his report, he summarized that his performance effectively supported scientific decision-making by the board of directors and expressed his outlook for 2026, stating that he will continue to adhere to the principles of independence and impartiality, deepen communication with the board of directors and management, and strive to promote the continuous optimization of the company’s governance mechanism to ensure the long-term healthy development of the company.

Access a wealth of information and precise interpretations, all in the Sina Finance APP.